Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:desferrioxamine B
go back to main search page
Accession:CHEBI:4356 term browser browse the term
Definition:An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Synonyms:exact_synonym: N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide
 related_synonym: DFO;   DFOB;   Deferoxamin;   Deferrioxamine;   Desferrioxamine;   Formula=C25H48N6O8;   InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);   InChIKey=UBQYURCVBFRUQT-UHFFFAOYSA-N;   N(4)-{5-[acetyl(hydroxy)amino]pentyl}-N(1)-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N(1)-hydroxybutanediamide;   SMILES=CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN;   deferoxamina;   deferoxamine;   deferoxaminum;   deferrioxamine B
 xref: Beilstein:2514118;   CAS:70-51-9;   Chemspider:2867;   DrugBank:DB00746;   Drug_Central:792;   HMDB:HMDB0014884;   KEGG:C06940;   KEGG:D03670;   LINCS:LSM-6541;   LIPID_MAPS_instance:LMFA08020169
 xref_mesh: MESH:D003676
 xref: PMID:11239825;   PMID:18536609;   PMID:28156129;   PMID:28285915;   PMID:28318697;   PMID:28455567;   PMID:29182270;   PMID:30701380;   PMID:31035197;   PMID:31229836;   PMID:31846315;   PMID:32039778;   PMID:32572744;   PMID:32734456;   PMID:32856363;   PMID:33784308;   Patent:BE609053;   Wikipedia:Deferoxamine
 cyclic_relationship: is_conjugate_acid_of CHEBI:84700;   is_conjugate_base_of CHEBI:195191


show annotations for term's descendants           Sort by:
desferrioxamine B term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aco1 aconitase 1 increases activity
multiple interactions
increases expression		 EXP
ISO		 Deferoxamine results in increased activity of ACO1 protein
[Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein
Deferoxamine results in increased expression of ACO1 protein		 CTD PMID:10397746 PMID:11054110 PMID:15893546 PMID:16568477 PMID:18073202 More... NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391 		JBrowse link
G Aco2 aconitase 2 decreases expression EXP Deferoxamine results in decreased expression of ACO2 protein CTD PMID:16568477 PMID:17469137 NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261 		JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant decreases activity
multiple interactions		 ISO Deferoxamine results in decreased activity of ACP5 protein
Deferoxamine inhibits the reaction [TF protein results in increased activity of ACP5 protein]; TF protein inhibits the reaction [Deferoxamine results in decreased activity of ACP5 protein]		 CTD PMID:31238089 NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929 		JBrowse link
G Acsl4 acyl-CoA synthetase long-chain family member 4 multiple interactions ISO Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA] CTD PMID:36843388 NCBI chr  X:105,942,794...106,006,573
Ensembl chr  X:105,942,799...106,006,427 		JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression
multiple interactions
increases expression		 EXP
ISO		 Deferoxamine results in decreased expression of ACTA2 protein
Deferoxamine inhibits the reaction [Artesunate results in decreased expression of ACTA2 mRNA]
Deferoxamine results in increased expression of ACTA2 mRNA		 CTD PMID:18032466 PMID:30551460 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Adm adrenomedullin increases expression ISO Deferoxamine results in increased expression of ADM mRNA CTD PMID:11754965 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP
ISO		 Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased phosphorylation of AKT1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of AKT1 protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA]		 CTD PMID:18032466 PMID:34577062 PMID:35690295 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of ALDH3A1 mRNA
Deferoxamine inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]		 CTD PMID:14645679 NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of ALPL mRNA
Deferoxamine results in decreased expression of ALPL protein
Indomethacin promotes the reaction [Deferoxamine results in decreased expression of ALPL protein]; Sulindac promotes the reaction [Deferoxamine results in decreased expression of ALPL protein]		 CTD PMID:16772336 PMID:21882223 NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446 		JBrowse link
G Anxa3 annexin A3 multiple interactions
decreases expression		 ISO ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ANXA3 protein]
Deferoxamine results in decreased expression of ANXA3 protein		 CTD PMID:19515424 NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617 		JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA] CTD PMID:33962019 PMID:35690295 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540 		JBrowse link
G App amyloid beta precursor protein affects binding
multiple interactions		 ISO Deferoxamine binds to APP 5' UTR
[Deferoxamine binds to APP 5' UTR] which results in decreased expression of APP protein; [Deferoxamine binds to APP 5' UTR] which results in decreased secretion of APP protein modified form; Deferoxamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal]		 CTD PMID:15681799 PMID:17964426 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561 		JBrowse link
G Aqp4 aquaporin 4 multiple interactions EXP Deferoxamine inhibits the reaction [manganese(III) acetate dihydrate results in increased expression of AQP4 protein] CTD PMID:20648640 NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856 		JBrowse link
G Arhgdia Rho GDP dissociation inhibitor alpha decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of ARHGDIA protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ARHGDIA protein]		 CTD PMID:19515424 NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023 		JBrowse link
G Arnt aryl hydrocarbon receptor nuclear translocator increases activity
increases expression
multiple interactions		 EXP
ISO		 Deferoxamine results in increased activity of ARNT protein
Deferoxamine results in increased expression of ARNT mRNA
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA]		 CTD PMID:10559391 PMID:33962019 PMID:35690295 NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580 		JBrowse link
G Ash2l ASH2 like histone lysine methyltransferase complex subunit increases expression
affects expression		 ISO Deferoxamine results in increased expression of ASH2L mRNA
Deferoxamine affects the expression of ASH2L mRNA		 CTD PMID:23483119 NCBI chr16:66,242,205...66,264,064
Ensembl chr16:66,242,212...66,264,061 		JBrowse link
G Atf1 activating transcription factor 1 increases activity EXP Deferoxamine results in increased activity of ATF1 protein CTD PMID:10559391 NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670 		JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO Deferoxamine results in increased phosphorylation of and results in increased activity of ATM protein CTD PMID:16959548 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437 		JBrowse link
G Atp6v0d2 ATPase H+ transporting V0 subunit D2 multiple interactions
affects expression		 ISO Deferoxamine affects the reaction [TF protein affects the expression of ATP6V0D2 mRNA]; TF protein affects the reaction [Deferoxamine affects the expression of ATP6V0D2 mRNA] CTD PMID:31238089 NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354 		JBrowse link
G Atp7a ATPase copper transporting alpha increases expression
multiple interactions		 EXP Deferoxamine results in increased expression of ATP7A mRNA
cupric chloride promotes the reaction [Deferoxamine results in increased expression of ATP7A mRNA]; Deferoxamine promotes the reaction [cupric chloride results in increased expression of ATP7A protein]		 CTD PMID:23174565 NCBI chr  X:71,094,144...71,201,550
Ensembl chr  X:71,094,202...71,198,354 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO [Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA] CTD PMID:33962019 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 ISO
EXP		 Deferoxamine results in increased expression of BAX mRNA; Deferoxamine results in increased expression of BAX protein
[Cisplatin co-treated with Deferoxamine] results in increased expression of BAX protein; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX protein; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of BAX protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; TP53 protein affects the reaction [Deferoxamine results in increased expression of BAX protein]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of BAX mRNA]		 CTD PMID:16800926 PMID:21742779 PMID:33962019 PMID:34126102 PMID:34577062 More... NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of BBC3 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA]		 CTD PMID:33962019 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression		 EXP
ISO		 Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased expression of BCL2 mRNA]; Deferoxamine inhibits the reaction [Copper Sulfate results in decreased expression of BCL2 mRNA]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA]
Deferoxamine results in decreased expression of BCL2 mRNA		 CTD PMID:30431687 PMID:33962019 PMID:34577062 PMID:35690295 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l15 Bcl2-like 15 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of BCL2L15 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA]		 CTD PMID:33962019 NCBI chr 2:191,338,959...191,344,078
Ensembl chr 2:191,338,959...191,344,078 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions EXP Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of BDNF protein] CTD PMID:34577062 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615 		JBrowse link
G Becn1 beclin 1 multiple interactions ISO Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of BECN1 protein]; Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of BECN1 protein] CTD PMID:21742779 PMID:32687844 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA] CTD PMID:33962019 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Bmp6 bone morphogenetic protein 6 multiple interactions
decreases expression		 ISO Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]
Deferoxamine results in decreased expression of BMP6 mRNA		 CTD PMID:25633564 PMID:32816093 NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365 		JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of BNIP3 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA]		 CTD PMID:33962019 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Bnip3l BCL2 interacting protein 3 like increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of BNIP3L mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA]		 CTD PMID:11832486 PMID:33962019 NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803 		JBrowse link
G C5 complement C5 multiple interactions ISO Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased cleavage of C5 protein]; Deferoxamine inhibits the reaction [Asbestos, Serpentine results in increased cleavage of C5 protein] CTD PMID:10777245 NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994 		JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H increases expression EXP Deferoxamine results in increased expression of CACNA1H mRNA CTD PMID:12679337 NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376 		JBrowse link
G Car2 carbonic anhydrase 2 decreases expression ISO Deferoxamine results in decreased expression of CAR2 mRNA CTD PMID:31238089 NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818 		JBrowse link
G Car9 carbonic anhydrase 9 increases expression ISO Deferoxamine results in increased expression of CA9 mRNA CTD PMID:25351418 NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838 		JBrowse link
G Casp12 caspase 12 multiple interactions ISO Deferoxamine promotes the reaction [manganese chloride results in increased cleavage of and results in increased activity of CASP12 protein] CTD PMID:23764342 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037 		JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions
increases activity		 ISO
EXP		 Deferoxamine results in increased expression of CASP3 protein
Deferoxamine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of CASP3 mRNA]; Deferoxamine inhibits the reaction [Copper Sulfate results in increased secretion of CASP3 protein]; Deferoxamine inhibits the reaction [Manganese results in increased activity of CASP3 protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; Deferoxamine inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Deferoxamine inhibits the reaction [Diquat results in increased cleavage of CASP3 protein]; Deferoxamine inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Deferoxamine promotes the reaction [manganese chloride results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP3 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased activity of CASP3 protein]
Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]		 CTD PMID:11933051 PMID:12523938 PMID:16374551 PMID:16800926 PMID:23764342 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 increases activity
multiple interactions		 ISO Deferoxamine results in increased activity of CASP8 protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; Nitroprusside inhibits the reaction [Deferoxamine results in increased activity of CASP8 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased activity of CASP8 protein]		 CTD PMID:16374551 PMID:33962019 PMID:35690295 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased activity of CASP9 protein] CTD PMID:12540492 PMID:14766669 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cat catalase multiple interactions EXP
ISO		 Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased activity of CAT protein]; Deferoxamine inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein]
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CAT mRNA		 CTD PMID:22115772 PMID:34577062 PMID:35690295 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cav1 caveolin 1 increases expression ISO Deferoxamine results in increased expression of CAV1 protein CTD PMID:16927372 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions EXP Deferoxamine inhibits the reaction [[Lipopolysaccharides co-treated with Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein] CTD PMID:25813056 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccna2 cyclin A2 decreases expression ISO Deferoxamine results in decreased expression of CCNA2 protein CTD PMID:11468187 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577 		JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO Deferoxamine results in decreased expression of CCNB1 protein CTD PMID:11468187 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 decreases expression ISO Deferoxamine results in decreased expression of CCND1 protein CTD PMID:11468187 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO Deferoxamine results in decreased expression of CCND2 protein CTD PMID:11468187 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495 		JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO Deferoxamine results in decreased expression of CCND3 protein CTD PMID:11468187 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371 		JBrowse link
G Ccne1 cyclin E1 increases expression ISO Deferoxamine results in increased expression of CCNE1 protein CTD PMID:11468187 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Cd36 CD36 molecule decreases expression ISO Deferoxamine results in decreased expression of CD36 protein CTD PMID:24170104 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903 		JBrowse link
G Cdc14a cell division cycle 14A increases expression ISO Deferoxamine results in increased expression of CDC14A mRNA alternative form CTD PMID:16760464 NCBI chr 2:204,225,540...204,380,927
Ensembl chr 2:204,225,540...204,380,927 		JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases activity
decreases expression		 ISO Deferoxamine results in decreased activity of CDK2 protein
Deferoxamine results in decreased expression of CDK2 protein		 CTD PMID:11468187 PMID:17631934 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
decreases expression
multiple interactions		 ISO
EXP		 Deferoxamine results in increased expression of CDKN1A mRNA; Deferoxamine results in increased expression of CDKN1A protein
Deferoxamine results in decreased expression of CDKN1A protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA]		 CTD PMID:10397746 PMID:10559391 PMID:11468187 PMID:12807743 PMID:16227210 More... NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1B mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA] CTD PMID:33962019 PMID:35690295 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A decreases expression ISO
EXP		 Deferoxamine results in decreased expression of CDKN2A protein CTD PMID:38483099 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149 		JBrowse link
G Ckb creatine kinase B multiple interactions EXP [Deferoxamine co-treated with Acetylcysteine] inhibits the reaction [Acetaminophen results in decreased activity of CKB protein]; [Deferoxamine co-treated with Acetylcysteine] inhibits the reaction [Carbon Tetrachloride results in decreased activity of CKB protein] CTD PMID:19688255 NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions EXP Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of COL1A1 mRNA] CTD PMID:11306436 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Cox4i1 cytochrome c oxidase subunit 4i1 multiple interactions ISO Deferoxamine inhibits the reaction [EPAS1 protein results in increased degradation of COX4I1 protein] CTD PMID:18515279 NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921 		JBrowse link
G Cp ceruloplasmin multiple interactions ISO Deferoxamine inhibits the reaction [CP protein results in increased oxidation of 3-carboxy-2,2,5,5-tetramethylpyrrolidin-1-yloxyl] CTD PMID:22824865 NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 increases activity EXP Deferoxamine results in increased activity of CREB1 protein CTD PMID:10559391 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816 		JBrowse link
G Crp C-reactive protein multiple interactions EXP Deferoxamine inhibits the reaction [Copper Sulfate results in increased secretion of CRP protein] CTD PMID:30431687 NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of CSF2 mRNA] CTD PMID:20801209 PMID:21703343 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Oxygen deficiency co-treated with Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] affects the localization of CTNNB1 protein; Deferoxamine inhibits the reaction [ferumoxides results in increased activity of CTNNB1 protein] CTD PMID:20338187 PMID:34648812 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Ctsk cathepsin K multiple interactions
decreases expression		 ISO Deferoxamine inhibits the reaction [TF protein results in increased expression of CTSK mRNA]; TF protein affects the reaction [Deferoxamine results in decreased expression of CTSK mRNA] CTD PMID:31238089 NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions EXP Deferoxamine promotes the reaction [Asbestos, Amphibole results in increased expression of CXCL2] CTD PMID:21605006 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO [Deferoxamine co-treated with Benzene] results in increased expression of CYBB protein; Deferoxamine inhibits the reaction [Benzene results in increased expression of CYBB mRNA] CTD PMID:35661779 NCBI chr  X:13,358,101...13,392,570
Ensembl chr  X:13,359,430...13,392,586 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions
increases expression		 ISO [Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA]
Deferoxamine results in increased expression of CYCS mRNA		 CTD PMID:33962019 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 mRNA]
Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]		 CTD PMID:10799651 PMID:10823667 PMID:20801209 PMID:21703343 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP Deferoxamine inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine] CTD PMID:7710944 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases expression ISO Deferoxamine results in decreased expression of CYP3A4 mRNA; Deferoxamine results in decreased expression of CYP3A4 protein CTD PMID:19695866 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO Deferoxamine promotes the reaction [manganese chloride results in increased expression of DDIT3 protein] CTD PMID:23764342 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Des desmin multiple interactions
increases expression		 ISO Deferoxamine inhibits the reaction [Artesunate results in decreased expression of DES mRNA]
Deferoxamine results in increased expression of DES mRNA		 CTD PMID:30551460 NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699 		JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of DIABLO mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA]		 CTD PMID:33962019 NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387 		JBrowse link
G Dicer1 dicer 1 ribonuclease III decreases expression ISO Deferoxamine results in decreased expression of DICER1 mRNA; Deferoxamine results in decreased expression of DICER1 protein CTD PMID:25351418 NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965 		JBrowse link
G Dio2 iodothyronine deiodinase 2 increases activity EXP Deferoxamine results in increased activity of DIO2 protein CTD PMID:17615150 NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809 		JBrowse link
G Dnm1l dynamin 1-like multiple interactions ISO Deferoxamine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]
[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA]		 CTD PMID:26318285 PMID:33962019 NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482 		JBrowse link
G Dnmt1 DNA methyltransferase 1 increases expression
decreases expression		 ISO Deferoxamine results in increased expression of DNMT1 mRNA
Deferoxamine results in decreased expression of DNMT1 mRNA		 CTD PMID:23483119 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659 		JBrowse link
G Dnmt3a DNA methyltransferase 3 alpha decreases expression
increases expression		 ISO Deferoxamine results in decreased expression of DNMT3A mRNA
Deferoxamine results in increased expression of DNMT3A mRNA		 CTD PMID:23483119 NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687 		JBrowse link
G Dnmt3b DNA methyltransferase 3 beta decreases expression
increases expression		 ISO Deferoxamine results in decreased expression of DNMT3B mRNA
Deferoxamine results in increased expression of DNMT3B mRNA		 CTD PMID:23483119 NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124 		JBrowse link
G Duox1 dual oxidase 1 multiple interactions ISO Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of DUOX1 mRNA] CTD PMID:21703343 NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563 		JBrowse link
G Duox2 dual oxidase 2 multiple interactions ISO Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of DUOX2 mRNA] CTD PMID:21703343 NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902 		JBrowse link
G Dusp1 dual specificity phosphatase 1 increases expression EXP Deferoxamine results in increased expression of DUSP1 mRNA CTD PMID:11577072 NCBI chr10:16,680,478...16,683,275 JBrowse link
G Edn1 endothelin 1 increases expression EXP Deferoxamine results in increased expression of EDN1 protein CTD PMID:9357851 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA; Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA] CTD PMID:15626777 PMID:35690295 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Egln1 egl-9 family hypoxia-inducible factor 1 decreases expression ISO Deferoxamine results in decreased expression of EGLN1 protein CTD PMID:22245592 NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777 		JBrowse link
G Ehmt2 euchromatic histone lysine methyltransferase 2 decreases expression ISO Deferoxamine results in decreased expression of EHMT2 mRNA CTD PMID:23483119 NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547 		JBrowse link
G Elane elastase, neutrophil expressed multiple interactions ISO Deferoxamine inhibits the reaction [ELANE protein results in increased expression of MUC5AC mRNA] CTD PMID:11919081 NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100 		JBrowse link
G Eno1 enolase 1 increases expression ISO Deferoxamine results in increased expression of ENO1 mRNA CTD PMID:16227210 NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336 		JBrowse link
G Epas1 endothelial PAS domain protein 1 multiple interactions
increases stability
increases expression		 ISO
EXP		 Deferoxamine inhibits the reaction [EPAS1 protein results in increased degradation of COX4I1 protein]
Deferoxamine results in increased stability of EPAS1 protein
Deferoxamine results in increased expression of EPAS1 protein		 CTD PMID:18353899 PMID:18515279 PMID:21558026 PMID:22447124 PMID:26735578 More... NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228 		JBrowse link
G Epo erythropoietin increases expression
multiple interactions
increases stability		 ISO
EXP		 Deferoxamine results in increased expression of EPO mRNA
Deferoxamine inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein]
Deferoxamine results in increased expression of EPO mRNA; Deferoxamine results in increased expression of EPO protein
Deferoxamine deficiency results in increased stability of EPO mRNA
Deferoxamine deficiency results in increased expression of EPO mRNA; Deferoxamine results in increased expression of EPO mRNA		 CTD PMID:9927288 PMID:10559391 PMID:10699462 PMID:10756076 PMID:21558026 NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO Deferoxamine promotes the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] CTD PMID:32283200 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Ero1a endoplasmic reticulum oxidoreductase 1 alpha increases expression ISO
EXP		 Deferoxamine results in increased expression of ERO1A mRNA CTD PMID:12752442 NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478 		JBrowse link
G Erp29 endoplasmic reticulum protein 29 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of ERP29 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ERP29 protein]		 CTD PMID:19515424 NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376 		JBrowse link
G Exo1 exonuclease 1 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA] CTD PMID:35690295 NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654 		JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions ISO Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased expression of F3 mRNA] CTD PMID:25858758 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668 		JBrowse link
G Fabp4 fatty acid binding protein 4 decreases expression ISO Deferoxamine results in decreased expression of FABP4 mRNA CTD PMID:12032628 NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of FASN protein]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of FASN protein] CTD PMID:34648812 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Fech ferrochelatase decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of FECH protein
ferric chloride inhibits the reaction [Deferoxamine results in decreased expression of FECH protein]		 CTD PMID:30517741 NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348 		JBrowse link
G Fis1 fission, mitochondrial 1 multiple interactions ISO [Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA] CTD PMID:33962019 NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377 		JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO Deferoxamine inhibits the reaction [Artesunate results in decreased expression of FN1 mRNA] CTD PMID:30551460 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Fth1 ferritin heavy chain 1 decreases expression
multiple interactions		 ISO
EXP		 Deferoxamine results in decreased expression of FTH1 protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTH1 mRNA
Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; Deferoxamine inhibits the reaction [beta-lapachone results in decreased expression of FTH1 protein]; Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in decreased expression of FTH1 protein]
Deferoxamine inhibits the reaction [Benzene results in increased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [Iron-Dextran Complex results in increased expression of FTH1 protein]		 CTD PMID:15893546 PMID:16568477 PMID:16777245 PMID:17469137 PMID:32687844 More... NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424 		JBrowse link
G Ftl1 ferritin light chain 1 multiple interactions
decreases expression		 ISO
EXP		 [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Deferoxamine inhibits the reaction [Phosphorus analog results in increased expression of FTL protein]
Deferoxamine results in decreased expression of FTL1 protein
Deferoxamine inhibits the reaction [Benzene results in increased expression of FTL1 protein]
Deferoxamine results in decreased expression of FTL protein		 CTD PMID:12393473 PMID:12644586 PMID:15893546 PMID:16568477 PMID:35661779 More... NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725 		JBrowse link
G Ftmt ferritin mitochondrial multiple interactions ISO Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]] CTD PMID:12644586 NCBI chr18:45,758,874...45,760,123
Ensembl chr18:45,758,874...45,760,123 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO Deferoxamine results in increased expression of GADD45A mRNA CTD PMID:10397746 PMID:11468187 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of GAPDH protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GAPDH protein]		 CTD PMID:19515424 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235 		JBrowse link
G Gas1 growth arrest-specific 1 multiple interactions ISO [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of GAS1 mRNA CTD PMID:12393473 NCBI chr17:4,482,168...4,485,153 JBrowse link
G Gbe1 1,4-alpha-glucan branching enzyme 1 increases expression ISO Deferoxamine results in increased expression of GBE1 mRNA CTD PMID:15094311 NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210 		JBrowse link
G Gck glucokinase affects expression EXP Deferoxamine affects the expression of GCK mRNA CTD PMID:9761743 NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO Deferoxamine inhibits the reaction [Benzene results in decreased expression of GCLC mRNA] CTD PMID:35661779 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Glb1 galactosidase, beta 1 increases expression EXP
ISO		 Deferoxamine results in increased expression of GLB1 protein CTD PMID:38483099 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127 		JBrowse link
G Glo1 glyoxalase 1 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of GLO1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GLO1 protein]		 CTD PMID:19515424 NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649 		JBrowse link
G Gosr1 golgi SNAP receptor complex member 1 multiple interactions ISO GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]] CTD PMID:31066958 NCBI chr10:61,570,499...61,607,287
Ensembl chr10:61,450,494...61,607,177
Ensembl chr10:61,450,494...61,607,177 		JBrowse link
G Gpx4 glutathione peroxidase 4 multiple interactions ISO Deferoxamine inhibits the reaction [Benzene results in decreased expression of GPX4 mRNA]; Deferoxamine inhibits the reaction [Benzene results in decreased expression of GPX4 protein]; Deferoxamine inhibits the reaction [Busulfan results in decreased expression of GPX4 mRNA]; Deferoxamine inhibits the reaction [Busulfan results in decreased expression of GPX4 protein]
Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]; Deferoxamine inhibits the reaction [Phosphorus analog results in decreased expression of GPX4 protein]		 CTD PMID:32416107 PMID:35661779 PMID:36843388 PMID:38220133 PMID:38653377 NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982 		JBrowse link
G Gsdme gasdermin E multiple interactions ISO Deferoxamine inhibits the reaction [Diquat results in increased cleavage of GSDME protein] CTD PMID:38128689 NCBI chr 4:79,258,799...79,321,129
Ensembl chr 4:79,257,804...79,320,806 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
decreases phosphorylation		 ISO
EXP		 Deferoxamine inhibits the reaction [Fenretinide results in increased phosphorylation of GSK3B protein]
Deferoxamine results in decreased phosphorylation of GSK3B protein
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in decreased phosphorylation of GSK3B protein]		 CTD PMID:25246272 PMID:34577062 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP Deferoxamine inhibits the reaction [Potassium Dichromate results in decreased activity of GSR protein] CTD PMID:22115772 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G H2ax H2A.X variant histone decreases expression ISO
EXP		 Deferoxamine results in decreased expression of H2AX protein CTD PMID:38483099 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 		JBrowse link
G Hamp hepcidin antimicrobial peptide multiple interactions
affects expression
decreases expression		 ISO
EXP		 Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Deferoxamine promotes the reaction [ferric ammonium citrate results in decreased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]
Deferoxamine affects the expression of HAMP mRNA
Deferoxamine results in decreased expression of HAMP protein		 CTD PMID:21558026 PMID:25633564 NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891 		JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of HAVCR1 protein] CTD PMID:30431687 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions
affects localization
decreases degradation
increases activity
increases stability
increases expression		 ISO
EXP		 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Doxorubicin co-treated with Deferoxamine] results in increased expression of HIF1A protein; [Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA; [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Arsenic Trioxide promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; Cadmium inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HIF1A mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HIF1A protein]]; Deferoxamine promotes the reaction [[HIF1A protein binds to VEGFA promoter] which results in increased expression of VEGFA mRNA]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Deferoxamine results in increased expression of and results in increased stability of HIF1A protein; Deferoxamine results in increased stability of and results in increased expression of HIF1A protein; dihydrotanshinone I inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ST6GAL1 protein promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]
Deferoxamine affects the localization of HIF1A protein
Deferoxamine results in decreased degradation of HIF1A protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Deferoxamine results in increased activity of TP53 protein] which results in increased ubiquitination of and results in increased degradation of and results in decreased expression of HIF1A protein]; [Deferoxamine results in increased activity of HIF1A protein] which results in decreased susceptibility to Carmustine; [Deferoxamine results in increased activity of TP53 protein] which results in increased ubiquitination of and results in increased degradation of and results in decreased expression of HIF1A protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]
Deferoxamine results in increased stability of HIF1A protein
Deferoxamine results in increased expression of HIF1A mRNA; Deferoxamine results in increased expression of HIF1A protein		 CTD PMID:10559391 PMID:10866824 PMID:11286986 PMID:12393473 PMID:14604972 More... NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hif3a hypoxia inducible factor 3 subunit alpha increases expression ISO Deferoxamine results in increased expression of HIF3A protein CTD PMID:16775626 NCBI chr 1:77,718,110...77,750,448
Ensembl chr 1:77,722,471...77,749,758 		JBrowse link
G Hk2 hexokinase 2 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of HK2 protein
Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HK2 mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of HK2 protein]]; Doxorubicin inhibits the reaction [Deferoxamine results in increased expression of HK2 protein]		 CTD PMID:34126102 PMID:36116563 NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression
decreases degradation		 ISO
EXP		 Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]
Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; Deferoxamine inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HMOX1 mRNA; Deferoxamine affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Fenretinide results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Zinc results in increased expression of HMOX1 mRNA]; Deferoxamine inhibits the reaction [Zinc results in increased expression of HMOX1 protein]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]]
Deferoxamine results in decreased expression of HMOX1 mRNA
Deferoxamine results in decreased degradation of HMOX1 protein		 CTD PMID:9747510 PMID:10814519 PMID:12393473 PMID:16439612 PMID:18073186 More... NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions
decreases expression		 ISO ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPA1A protein]
Deferoxamine results in decreased expression of HSPA1A protein		 CTD PMID:19515424 NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227 		JBrowse link
G Hspa1l heat shock protein family A (Hsp70) member 1 like multiple interactions ISO [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA1L mRNA CTD PMID:12393473 NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571 		JBrowse link
G Hspa6l-ps1 heat shock protein family A (Hsp70) member 6 like, pseudogene 1 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA] CTD PMID:35690295 NCBI chr13:83,273,176...83,274,317 JBrowse link
G Hspa9 heat shock protein family A (Hsp70) member 9 multiple interactions ISO [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA9 mRNA CTD PMID:12393473 NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292 		JBrowse link
G Hspd1 heat shock protein family D (Hsp60) member 1 multiple interactions
decreases expression		 ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA; ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPD1 protein]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA]
Deferoxamine results in decreased expression of HSPD1 protein		 CTD PMID:19515424 PMID:24170104 PMID:35690295 NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662 		JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 multiple interactions ISO [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPH1 mRNA CTD PMID:12393473 NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] CTD PMID:12633744 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Il10 interleukin 10 multiple interactions EXP Deferoxamine inhibits the reaction [Copper Sulfate results in decreased secretion of IL10 protein] CTD PMID:30431687 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of IL1A mRNA] CTD PMID:21703343 NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
increases expression		 ISO Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; Deferoxamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; ferric chloride inhibits the reaction [Deferoxamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]
Deferoxamine results in decreased expression of IL1B mRNA
Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL1B protein]
Deferoxamine results in increased expression of IL1B mRNA		 CTD PMID:9851740 PMID:18403674 PMID:20801209 PMID:32816093 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il4 interleukin 4 multiple interactions EXP Deferoxamine inhibits the reaction [Mercuric Chloride results in increased expression of IL4 mRNA] CTD PMID:11222498 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO
EXP		 Deferoxamine inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of and results in increased secretion of IL6 protein]; Deferoxamine inhibits the reaction [Coal Ash results in increased expression of IL6 protein]
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of IL6 protein]; Deferoxamine inhibits the reaction [Asbestos, Amphibole results in increased expression of IL6 mRNA]		 CTD PMID:9344885 PMID:22168577 PMID:24296301 PMID:34577062 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Ins1 insulin 1 increases secretion EXP Deferoxamine results in increased secretion of INS1 protein CTD PMID:30382123 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536 		JBrowse link
G Ireb2 iron responsive element binding protein 2 increases expression
multiple interactions
increases activity		 EXP
ISO		 Deferoxamine results in increased expression of IREB2 protein
Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein]; Deferoxamine results in increased expression of and results in increased activity of IREB2 protein
Deferoxamine results in increased activity of IREB2 protein		 CTD PMID:10397746 PMID:11054110 PMID:16135072 PMID:16568477 PMID:17469137 More... NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611 		JBrowse link
G Itgb3 integrin subunit beta 3 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of ITGB3 mRNA
Deferoxamine inhibits the reaction [TF protein results in increased expression of ITGB3 mRNA]		 CTD PMID:31238089 NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Deferoxamine results in decreased abundance of Iron] which results in increased expression of JUN mRNA CTD PMID:12393473 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Kdm1a lysine demethylase 1A multiple interactions ISO Deferoxamine results in decreased expression of and results in decreased activity of KDM1A protein CTD PMID:23483119 NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319 		JBrowse link
G Kdm3a lysine demethylase 3A increases expression ISO Deferoxamine results in increased expression of KDM3A protein CTD PMID:23546878 NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073 		JBrowse link
G Kdm4a lysine demethylase 4A multiple interactions ISO Deferoxamine results in decreased expression of and results in decreased activity of KDM4A protein CTD PMID:23483119 NCBI chr 5:131,672,754...131,719,534
Ensembl chr 5:131,672,754...131,719,501 		JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO [Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA] CTD PMID:33962019 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Lcn2 lipocalin 2 multiple interactions
increases expression		 ISO Deferoxamine affects the reaction [Magnetite Nanoparticles results in increased expression of LCN2 mRNA]; Deferoxamine inhibits the reaction [LCN2 protein results in decreased secretion of VEGFA protein]
Deferoxamine results in increased expression of LCN2 mRNA		 CTD PMID:17114340 PMID:23086747 NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095 		JBrowse link
G Ldha lactate dehydrogenase A increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of LDHA mRNA
Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of LDHA mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of LDHA protein]]		 CTD PMID:34998824 PMID:36116563 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472 		JBrowse link
G Lep leptin increases expression
increases secretion		 ISO
EXP		 Deferoxamine results in increased expression of LEP mRNA
Deferoxamine results in increased secretion of LEP protein		 CTD PMID:12032628 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262 		JBrowse link
G Lipe lipase E, hormone sensitive type decreases expression ISO Deferoxamine results in decreased expression of LIPE mRNA CTD PMID:12032628 NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310 		JBrowse link
G Lox lysyl oxidase multiple interactions ISO [Deferoxamine results in decreased abundance of Iron] which results in increased expression of LOX mRNA CTD PMID:12393473 NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477 		JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha multiple interactions ISO Deferoxamine inhibits the reaction [Hydrogen Peroxide affects the localization of MAP1LC3A protein] CTD PMID:21742779 NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of MAP1LC3B protein
Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein]		 CTD PMID:25301941 PMID:32687844 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAP3K5 protein] CTD PMID:20206247 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation		 EXP
ISO		 Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; Deferoxamine promotes the reaction [Manganese results in increased phosphorylation of MAPK1 protein]
Deferoxamine results in increased phosphorylation of MAPK1 protein
[Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK1 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]
Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK1 protein]]		 CTD PMID:11933051 PMID:16527254 PMID:18032466 PMID:20368581 PMID:31066958 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation		 EXP
ISO		 Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK3 protein]; Deferoxamine promotes the reaction [Manganese results in increased phosphorylation of MAPK3 protein]
Deferoxamine results in increased phosphorylation of MAPK3 protein
[Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK3 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]
Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]; GOSR1 protein affects the reaction [Deferoxamine inhibits the reaction [Nitroprusside results in decreased phosphorylation of MAPK3 protein]]		 CTD PMID:11933051 PMID:16527254 PMID:18032466 PMID:20368581 PMID:31066958 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions		 ISO Deferoxamine results in increased phosphorylation of MAPK8 protein
Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK8 protein]		 CTD PMID:20206247 PMID:20368581 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions		 ISO Deferoxamine results in increased phosphorylation of MAPK9 protein
Deferoxamine inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK9 protein]		 CTD PMID:20206247 PMID:20368581 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases cleavage		 ISO Nitroprusside inhibits the reaction [Deferoxamine results in increased cleavage of MCL1 protein]; Vanadates inhibits the reaction [Deferoxamine results in increased cleavage of MCL1 protein] CTD PMID:16374551 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression EXP Deferoxamine results in increased expression of MDM2 protein CTD PMID:19950214 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915 		JBrowse link
G Mff mitochondrial fission factor increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of MFF mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA]		 CTD PMID:33962019 NCBI chr 9:84,007,798...84,036,039
Ensembl chr 9:84,007,798...84,036,039 		JBrowse link
G Mfn2 mitofusin 2 multiple interactions ISO [Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA; Melatonin affects the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA] CTD PMID:33962019 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342 		JBrowse link
G Mief2 mitochondrial elongation factor 2 multiple interactions
increases expression		 ISO [Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA]
Deferoxamine results in increased expression of MIEF2 mRNA		 CTD PMID:33962019 NCBI chr10:45,408,055...45,414,144
Ensembl chr10:45,408,082...45,414,144 		JBrowse link
G Mir155 microRNA 155 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA] CTD PMID:35690295 NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718 		JBrowse link
G Mir184 microRNA 184 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR184 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in decreased expression of BCL2 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of AKT1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of APAF1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of ARNT mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of BAX mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP3 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CASP8 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EGFR mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of EXO1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HIF1A mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA6 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of HSPD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MIR155 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA] CTD PMID:35690295 NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210 		JBrowse link
G Mir210 microRNA 210 increases expression
increases expression 		ISO Deferoxamine results in increased expression of MIR210 mRNA
desferrioxamine B increases expression of MIR210 miRNA in trophoblast cells 		CTD
RGD		 PMID:24577088 PMID:22840297 RGD:155631283 NCBI chr 1:196,326,343...196,326,452
Ensembl chr 1:196,326,337...196,326,454 		JBrowse link
G Mlh1 mutL homolog 1 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MLH1 mRNA] CTD PMID:35690295 NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617 		JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO [Deferoxamine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [[Amitrole co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA] CTD PMID:10464329 PMID:19136476 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions
decreases activity		 ISO Calcium Chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]; Deferoxamine inhibits the reaction [ferumoxides results in increased activity of MMP2 protein]; ferric chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein] CTD PMID:10086886 PMID:20338187 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP3 mRNA] CTD PMID:35690295 NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression		 ISO Deferoxamine inhibits the reaction [TF protein results in increased expression of MMP9 mRNA]; TF protein affects the reaction [Deferoxamine results in increased expression of MMP9 mRNA]
Deferoxamine results in decreased expression of MMP9 mRNA
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MMP9 mRNA]		 CTD PMID:31238089 PMID:35690295 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mrps9 mitochondrial ribosomal protein S9 multiple interactions
increases expression		 ISO ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of MRPS9 protein] CTD PMID:19515424 NCBI chr 9:45,113,554...45,172,375
Ensembl chr 9:45,113,554...45,172,375 		JBrowse link
G Msr1 macrophage scavenger receptor 1 multiple interactions ISO Deferoxamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA] CTD PMID:9614211 NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676 		JBrowse link
G Mt-atp6 mitochondrially encoded ATP synthase membrane subunit 6 decreases expression ISO Deferoxamine results in decreased expression of ATP6 mRNA CTD PMID:31238089 NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599 		JBrowse link
G Mt-atp8 mitochondrially encoded ATP synthase membrane subunit 8 decreases expression ISO Deferoxamine results in decreased expression of ATP8 mRNA CTD PMID:31238089 NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
Ensembl chr MT:7,758...7,961 		JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I decreases expression ISO Deferoxamine results in decreased expression of COX1 mRNA CTD PMID:31238089 NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867 		JBrowse link
G Mt-co2 mitochondrially encoded cytochrome c oxidase II decreases expression ISO Deferoxamine results in decreased expression of COX2 mRNA CTD PMID:31238089 NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689 		JBrowse link
G Mt-co3 mitochondrially encoded cytochrome c oxidase III decreases expression ISO Deferoxamine results in decreased expression of COX3 mRNA CTD PMID:31238089 NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382 		JBrowse link
G Mt-cyb mitochondrially encoded cytochrome b decreases expression ISO Deferoxamine results in decreased expression of CYTB mRNA CTD PMID:31238089 NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278 		JBrowse link
G Mt-nd1 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 decreases expression ISO Deferoxamine results in decreased expression of ND1 mRNA CTD PMID:31238089 NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694 		JBrowse link
G Mt-nd2 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 decreases expression ISO Deferoxamine results in decreased expression of ND2 mRNA CTD PMID:31238089 NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
Ensembl chr MT:3,904...4,942 		JBrowse link
G Mt-nd3 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3 decreases expression ISO Deferoxamine results in decreased expression of ND3 mRNA CTD PMID:31238089 NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
Ensembl chr MT:9,451...9,798 		JBrowse link
G Mt-nd4 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 decreases expression ISO Deferoxamine results in decreased expression of ND4 mRNA CTD PMID:31238089 NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537 		JBrowse link
G Mt-nd4l mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L decreases expression ISO Deferoxamine results in decreased expression of ND4L mRNA CTD PMID:31238089 NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
Ensembl chr MT:9,870...10,166 		JBrowse link
G Mt-nd5 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 decreases expression ISO Deferoxamine results in decreased expression of ND5 mRNA CTD PMID:31238089 NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
NCBI chr MT:11,736...13,565
Ensembl chr MT:11,736...13,565 		JBrowse link
G Mt-nd6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 decreases expression ISO Deferoxamine results in decreased expression of ND6 mRNA CTD PMID:31238089 NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061 		JBrowse link
G Mt2A metallothionein 2A multiple interactions ISO [Deferoxamine results in decreased abundance of Iron] which results in increased expression of MT2A mRNA CTD PMID:12393473 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of MTOR mRNA] CTD PMID:35690295 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO Deferoxamine inhibits the reaction [ELANE protein results in increased expression of MUC5AC mRNA] CTD PMID:11919081 NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases degradation
multiple interactions
decreases expression		 ISO Deferoxamine results in increased degradation of MYC protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of MYC mRNA
Deferoxamine results in decreased expression of MYC protein		 CTD PMID:12393473 PMID:20046830 PMID:22245592 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Ncoa4 nuclear receptor coactivator 4 multiple interactions ISO Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; Deferoxamine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of NCOA4 protein]; Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of NCOA4 protein] CTD PMID:32283200 PMID:32687844 PMID:36843388 NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641
Ensembl chr16:7,366,542...7,409,641 		JBrowse link
G Ndrg1 N-myc downstream regulated 1 increases expression
decreases response to substance		 ISO Deferoxamine results in increased expression of NDRG1 mRNA; Deferoxamine results in increased expression of NDRG1 protein
NDRG1 protein results in decreased susceptibility to Deferoxamine		 CTD PMID:11006124 PMID:24532803 NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880 		JBrowse link
G Ndufb8 NADH:ubiquinone oxidoreductase subunit B8 decreases expression ISO Deferoxamine results in decreased expression of NDUFB8 protein CTD PMID:31238089 NCBI chr 1:243,408,656...243,413,715
Ensembl chr 1:243,408,619...243,413,817 		JBrowse link
G Nes nestin decreases expression ISO Deferoxamine results in decreased expression of NES mRNA CTD PMID:16772336 NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO Deferoxamine inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of NFE2L2 protein]; Deferoxamine inhibits the reaction [Nitroprusside results in decreased expression of NFE2L2 protein]; Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of NFE2L2 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]]
Deferoxamine inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein]		 CTD PMID:26945724 PMID:31066958 PMID:32416107 PMID:36450496 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions EXP Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of NFKBIA mRNA] CTD PMID:30431687 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression		 EXP
ISO		 Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Deferoxamine]
Deferoxamine results in increased expression of NOS2 mRNA
[Deferoxamine results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide		 CTD PMID:7532384 PMID:18073202 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of NQO1 mRNA
Deferoxamine inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]		 CTD PMID:14645679 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Olr1 oxidized low density lipoprotein receptor 1 decreases expression ISO Deferoxamine results in decreased expression of OLR1 protein CTD PMID:24170104 NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523 		JBrowse link
G Opa1 OPA1, mitochondrial dynamin like GTPase multiple interactions
increases expression		 ISO [Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA]
Deferoxamine results in increased expression of OPA1 mRNA		 CTD PMID:33962019 NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109 		JBrowse link
G P4ha1 prolyl 4-hydroxylase subunit alpha 1 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of P4HA1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of P4HA1 protein]		 CTD PMID:19515424 NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions		 ISO Deferoxamine results in increased cleavage of PARP1 protein
Indomethacin promotes the reaction [Deferoxamine results in increased cleavage of PARP1 protein]; Sulindac promotes the reaction [Deferoxamine results in increased cleavage of PARP1 protein]		 CTD PMID:21882223 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pdgfa platelet derived growth factor subunit A multiple interactions EXP Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of PDGFA mRNA] CTD PMID:11306436 NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497 		JBrowse link
G Pdgfb platelet derived growth factor subunit B multiple interactions EXP Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of AKT1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; Deferoxamine inhibits the reaction [PDGFB protein results in increased phosphorylation of MAPK3 protein] CTD PMID:18032466 NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984 		JBrowse link
G Pdgfrb platelet derived growth factor receptor beta decreases expression EXP Deferoxamine results in decreased expression of PDGFRB protein CTD PMID:18032466 NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843 		JBrowse link
G Pdhb pyruvate dehydrogenase E1 subunit beta increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of PDHB protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PDHB protein]		 CTD PMID:19515424 NCBI chr15:16,752,561...16,758,503
Ensembl chr15:16,750,980...16,758,500 		JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 increases expression ISO Deferoxamine results in increased expression of PDK1 mRNA CTD PMID:21558026 NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038 		JBrowse link
G Pfkfb4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 multiple interactions ISO [Deferoxamine results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA CTD PMID:16025159 NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634 		JBrowse link
G Pgk1 phosphoglycerate kinase 1 multiple interactions
decreases expression
increases expression		 ISO ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PGK1 protein]
Deferoxamine results in decreased expression of PGK1 protein
Deferoxamine results in increased expression of PGK1 mRNA		 CTD PMID:19515424 PMID:22447124 PMID:34998824 NCBI chr  X:71,271,454...71,287,429
Ensembl chr  X:71,271,440...71,287,418 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of PIK3R1 mRNA] CTD PMID:35690295 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Pink1 PTEN induced kinase 1 multiple interactions ISO [Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA] CTD PMID:33962019 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635 		JBrowse link
G Plagl2 PLAG1 like zinc finger 2 multiple interactions ISO Deferoxamine results in increased expression of and affects the localization of PLAGL2 protein CTD PMID:11832486 NCBI chr 3:141,695,322...141,708,516
Ensembl chr 3:141,695,322...141,708,503 		JBrowse link
G Plau plasminogen activator, urokinase multiple interactions ISO Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA] CTD PMID:17571974 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775 		JBrowse link
G Plin2 perilipin 2 multiple interactions ISO [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of PLIN2 protein]; Deferoxamine promotes the reaction [Oxygen deficiency results in increased expression of PLIN2 protein] CTD PMID:34648812 NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319 		JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of PMAIP1 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA]		 CTD PMID:33962019 NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429 		JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions ISO [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of PMP22 mRNA CTD PMID:12393473 NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO Deferoxamine results in increased expression of POU5F1 mRNA CTD PMID:22447124 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891 		JBrowse link
G Ppia peptidylprolyl isomerase A multiple interactions
decreases expression		 ISO ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PPIA protein]
Deferoxamine results in decreased expression of PPIA protein		 CTD PMID:19515424 NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601 		JBrowse link
G Prkcd protein kinase C, delta increases phosphorylation ISO Deferoxamine results in increased phosphorylation of PRKCD protein CTD PMID:17097691 NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases stability
increases expression
multiple interactions		 ISO Deferoxamine results in increased stability of PTGS2 protein
Deferoxamine results in increased expression of PTGS2 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; Deferoxamine inhibits the reaction [Benzene results in increased expression of PTGS2 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; [Sulindac co-treated with Deferoxamine] results in increased expression of PTGS2 protein; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]; Indomethacin promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]
Deferoxamine results in increased expression of PTGS2 mRNA; Deferoxamine results in increased expression of PTGS2 protein		 CTD PMID:16527254 PMID:21882223 PMID:32816093 PMID:35661779 PMID:36843388 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Rack1 receptor for activated C kinase 1 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of RACK1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of RACK1 protein]		 CTD PMID:19515424 NCBI chr10:33,169,415...33,174,896
Ensembl chr10:33,169,169...33,174,975 		JBrowse link
G Ramp2 receptor activity modifying protein 2 decreases expression ISO Deferoxamine results in decreased expression of RAMP2 mRNA CTD PMID:11754965 NCBI chr10:86,187,366...86,190,692
Ensembl chr10:86,188,812...86,231,829 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases phosphorylation ISO Deferoxamine results in decreased phosphorylation of RB1 protein CTD PMID:11468187 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of RELA protein] CTD PMID:34577062 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression ISO Deferoxamine results in decreased expression of RUNX2 mRNA CTD PMID:16772336 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167 		JBrowse link
G Sag S-antigen visual arrestin multiple interactions EXP Deferoxamine inhibits the reaction [SAG results in increased abundance of Free Radicals] CTD PMID:8407215 NCBI chr 9:88,467,797...88,508,821
Ensembl chr 9:88,469,376...88,508,820 		JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B decreases expression ISO Deferoxamine results in decreased expression of SDHB protein CTD PMID:31238089 NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293 		JBrowse link
G Sele selectin E multiple interactions ISO [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein] CTD PMID:12633744 NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741 		JBrowse link
G Sesn2 sestrin 2 multiple interactions ISO Deferoxamine inhibits the reaction [erastin results in increased expression of SESN2 protein] CTD PMID:31323261 NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260 		JBrowse link
G Setd1a SET domain containing 1A, histone lysine methyltransferase increases expression ISO Deferoxamine results in increased expression of SETD1A mRNA CTD PMID:23483119 NCBI chr 1:182,386,197...182,411,695
Ensembl chr 1:182,388,060...182,411,090 		JBrowse link
G Setd2 SET domain containing 2, histone lysine methyltransferase increases expression
affects expression		 ISO Deferoxamine results in increased expression of SETD2 mRNA
Deferoxamine affects the expression of SETD2 mRNA		 CTD PMID:23483119 NCBI chr 8:110,511,808...110,597,475
Ensembl chr 8:110,511,772...110,597,489 		JBrowse link
G Sirt1 sirtuin 1 increases expression ISO Deferoxamine results in increased expression of SIRT1 protein CTD PMID:22245592 NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Slc11a2 solute carrier family 11 member 2 multiple interactions
increases expression
decreases expression		 EXP
ISO		 [Deferoxamine co-treated with Manganese] results in increased expression of SLC11A2; [Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 protein]] which results in increased uptake of Copper; Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 mRNA]; Deferoxamine promotes the reaction [Doxorubicin results in increased expression of SLC11A2 protein]
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of SLC11A2 mRNA; [Deferoxamine results in increased expression of SLC11A2 protein] which results in increased uptake of Manganese; Deferoxamine promotes the reaction [Deferoxamine results in increased expression of SLC11A2 protein]
Deferoxamine results in decreased expression of SLC11A2 mRNA		 CTD PMID:11933051 PMID:12393473 PMID:23764342 PMID:24089420 NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145 		JBrowse link
G Slc19a2 solute carrier family 19 member 2 decreases expression ISO Deferoxamine results in decreased expression of SLC19A2 mRNA CTD PMID:34998824 NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172 		JBrowse link
G Slc19a3 solute carrier family 19 member 3 decreases expression ISO Deferoxamine results in decreased expression of SLC19A3 mRNA CTD PMID:34998824 NCBI chr 9:84,275,722...84,299,368
Ensembl chr 9:84,277,024...84,299,337 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 multiple interactions
increases expression		 ISO [Deferoxamine results in decreased abundance of Oxygen] which results in increased expression of SLC2A1 protein; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of SLC2A1 mRNA]]; Deferoxamine inhibits the reaction [myricetin inhibits the reaction [Formaldehyde results in increased expression of SLC2A1 protein]]
Deferoxamine results in increased expression of SLC2A1 mRNA		 CTD PMID:12032628 PMID:17442736 PMID:21558026 PMID:36116563 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416 		JBrowse link
G Slc2a4 solute carrier family 2 member 4 decreases expression ISO Deferoxamine results in decreased expression of SLC2A4 mRNA CTD PMID:12032628 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565 		JBrowse link
G Slc40a1 solute carrier family 40 member 1 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of SLC40A1 protein
Deferoxamine inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein]		 CTD PMID:31238089 PMID:32416107 NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481 		JBrowse link
G Slc44a4 solute carrier family 44, member 4 decreases expression ISO Deferoxamine results in decreased expression of SLC44A4 mRNA CTD PMID:34998824 NCBI chr20:3,903,099...3,919,215
Ensembl chr20:3,903,099...3,919,215 		JBrowse link
G Slc6a2 solute carrier family 6 member 2 decreases expression EXP Deferoxamine results in decreased expression of SLC6A2 protein CTD PMID:16650837 NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of SLC7A11 mRNA
Deferoxamine inhibits the reaction [Benzene results in decreased expression of SLC7A11 mRNA]; Deferoxamine inhibits the reaction [Busulfan results in decreased expression of SLC7A11 protein]; Deferoxamine promotes the reaction [Benzene results in decreased expression of SLC7A11 protein]
Deferoxamine affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of SLC7A11 protein]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA]		 CTD PMID:32816093 PMID:35661779 PMID:36450496 PMID:36843388 PMID:38220133 NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536 		JBrowse link
G Slpi secretory leukocyte peptidase inhibitor decreases expression ISO Deferoxamine results in decreased expression of SLPI mRNA CTD PMID:32816093 NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD1 mRNA] CTD PMID:35690295 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression		 ISO [Deferoxamine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of SOD2 mRNA; Deferoxamine inhibits the reaction [[Amitrole co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]; TRAP1 protein inhibits the reaction [Deferoxamine results in increased expression of SOD2 protein]
Deferoxamine inhibits the reaction [SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]]		 CTD PMID:10464329 PMID:16927372 PMID:19063909 PMID:35690295 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein] CTD PMID:12633744 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961 		JBrowse link
G Sp7 Sp7 transcription factor multiple interactions ISO Deferoxamine inhibits the reaction [Ascorbic Acid results in increased expression of SP7 mRNA] CTD PMID:21467157 NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847 		JBrowse link
G Sqstm1 sequestosome 1 increases expression
multiple interactions		 ISO Deferoxamine results in increased expression of SQSTM1 protein
[Copper co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; [Iron co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]		 CTD PMID:25301941 PMID:32283200 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Paclitaxel co-treated with FV-429 compound co-treated with Deferoxamine] promotes the reaction [Oxygen deficiency results in increased expression of SREBF1 protein] CTD PMID:34648812 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G St6gal1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1 multiple interactions ISO ST6GAL1 protein promotes the reaction [Deferoxamine results in increased expression of HIF1A protein] CTD PMID:29475939 NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions EXP Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of STAT3 protein] CTD PMID:30431687 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Suv39h1 SUV39H1 histone lysine methyltransferase increases expression
decreases expression		 ISO Deferoxamine results in increased expression of SUV39H1 mRNA
Deferoxamine results in decreased expression of SUV39H1 mRNA		 CTD PMID:23483119 NCBI chr  X:14,421,028...14,433,993
Ensembl chr  X:14,421,109...14,433,982 		JBrowse link
G Suv39h1-ps1 SUV39H1 histone lysine methyltransferase, pseudogene 1 decreases expression
increases expression		 ISO Deferoxamine results in decreased expression of SUV39H1 mRNA
Deferoxamine results in increased expression of SUV39H1 mRNA		 CTD PMID:23483119 NCBI chr  X:141,792,589...141,795,257 JBrowse link
G Tet2 tet methylcytosine dioxygenase 2 decreases expression ISO Deferoxamine results in decreased expression of TET2 protein CTD PMID:23483119 NCBI chr 2:221,988,645...222,072,813
Ensembl chr 2:221,988,645...222,072,534 		JBrowse link
G Tf transferrin multiple interactions ISO Deferoxamine affects the reaction [TF protein affects the expression of ATP6V0D2 mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased activity of ACP5 protein]; Deferoxamine inhibits the reaction [TF protein results in increased expression of CTSK mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased expression of ITGB3 mRNA]; Deferoxamine inhibits the reaction [TF protein results in increased expression of MMP9 mRNA]; TF protein affects the reaction [Deferoxamine affects the expression of ATP6V0D2 mRNA]; TF protein affects the reaction [Deferoxamine results in decreased expression of CTSK mRNA]; TF protein affects the reaction [Deferoxamine results in increased expression of MMP9 mRNA]; TF protein inhibits the reaction [Deferoxamine results in decreased activity of ACP5 protein] CTD PMID:31238089 NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511 		JBrowse link
G Tfr2 transferrin receptor 2 decreases expression ISO Deferoxamine results in decreased expression of TFR2 protein CTD PMID:25633564 NCBI chr12:19,107,673...19,124,622
Ensembl chr12:19,107,673...19,124,591 		JBrowse link
G Tfrc transferrin receptor increases expression
multiple interactions		 ISO
EXP		 Deferoxamine results in increased expression of TFRC mRNA; Deferoxamine results in increased expression of TFRC protein
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Deferoxamine results in decreased abundance of Oxygen] which results in increased expression of TFRC protein
[Deferoxamine co-treated with Benzene] results in increased expression of TFRC protein; Deferoxamine affects the reaction [Magnetite Nanoparticles results in decreased expression of TFRC mRNA]; Deferoxamine promotes the reaction [Busulfan results in decreased expression of TFRC protein]
Deferoxamine inhibits the reaction [Doxorubicin results in decreased expression of TFRC mRNA]		 CTD PMID:11054110 PMID:12393473 PMID:12807743 PMID:15993339 PMID:16039939 More... NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of TGFB1 mRNA] CTD PMID:11306436 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Th tyrosine hydroxylase increases expression EXP Deferoxamine results in increased expression of TH mRNA CTD PMID:9458725 NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767 		JBrowse link
G Tlr4 toll-like receptor 4 decreases expression ISO Deferoxamine results in decreased expression of TLR4 protein CTD PMID:24170104 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases activity
decreases expression
increases response to substance		 ISO
EXP		 [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNF mRNA; Deferoxamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Deferoxamine inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; ferrous sulfate inhibits the reaction [Deferoxamine results in decreased activity of TNF protein]
Deferoxamine results in decreased expression of TNF mRNA
Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of TNF protein]; Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of TNF protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Deferoxamine]
Deferoxamine results in increased susceptibility to TNF protein		 CTD PMID:7532384 PMID:7539275 PMID:9851740 PMID:10486238 PMID:12633744 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfaip6 TNF alpha induced protein 6 decreases expression ISO Deferoxamine results in decreased expression of TNFAIP6 mRNA CTD PMID:32816093 NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649 		JBrowse link
G Tnfrsf11a TNF receptor superfamily member 11A decreases expression ISO Deferoxamine results in decreased expression of TNFRSF11A mRNA CTD PMID:31238089 NCBI chr13:21,928,370...21,986,719
Ensembl chr13:21,928,408...21,986,695 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TNFSF10 mRNA] CTD PMID:35690295 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK1 protein; [Deferoxamine co-treated with TNFSF11 protein] results in decreased phosphorylation of MAPK3 protein; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]; Deferoxamine inhibits the reaction [[Hydrogen Peroxide co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein] CTD PMID:31238089 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases response to substance
increases expression
increases activity
decreases expression		 ISO
EXP		 [Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA; Antineoplastic Agents, Immunological inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA]; Deferoxamine inhibits the reaction [sodium bichromate results in increased expression of TP53 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of TP53 mRNA]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of HIF1A protein]; TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein]; TP53 protein affects the reaction [Deferoxamine results in increased expression of BAX protein]
TP53 protein results in decreased susceptibility to Deferoxamine
Deferoxamine results in increased expression of TP53 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Deferoxamine results in increased activity of TP53 protein] which results in increased ubiquitination of and results in increased degradation of and results in decreased expression of HIF1A protein]; [Deferoxamine results in increased activity of TP53 protein] which results in increased ubiquitination of and results in increased degradation of and results in decreased expression of HIF1A protein; Deferoxamine inhibits the reaction [[Copper Sulfate results in increased abundance of Copper] which results in increased expression of TP53 mRNA]
Deferoxamine results in decreased expression of TP53 protein		 CTD PMID:10942736 PMID:16357363 PMID:16527254 PMID:19950214 PMID:23483119 More... NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Tpd52l1 TPD52 like 1 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of TPD52L1 protein
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of TPD52L1 protein]		 CTD PMID:19515424 NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109 		JBrowse link
G Tpi1 triosephosphate isomerase 1 increases expression EXP Deferoxamine results in increased expression of TPI1 mRNA CTD PMID:14762718 NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541 		JBrowse link
G Trap1 TNF receptor-associated protein 1 decreases expression
multiple interactions		 ISO Deferoxamine results in decreased expression of TRAP1 mRNA; Deferoxamine results in decreased expression of TRAP1 protein
TRAP1 protein inhibits the reaction [Deferoxamine results in increased expression of SOD2 protein]		 CTD PMID:16927372 NCBI chr10:11,464,882...11,498,931
Ensembl chr10:11,464,821...11,498,981 		JBrowse link
G Tubb3 tubulin, beta 3 class III increases expression ISO Deferoxamine results in increased expression of TUBB3 mRNA CTD PMID:16772336 NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243 		JBrowse link
G Ucp2 uncoupling protein 2 decreases expression ISO Deferoxamine results in decreased expression of UCP2 mRNA CTD PMID:12032628 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO
EXP		 [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
Deferoxamine inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 protein]		 CTD PMID:12633744 PMID:30431687 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958 		JBrowse link
G Vdac2 voltage-dependent anion channel 2 multiple interactions
decreases expression		 ISO ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of VDAC2 protein]
Deferoxamine results in decreased expression of VDAC2 protein		 CTD PMID:19515424 NCBI chr15:2,462,877...2,476,802
Ensembl chr15:2,463,056...2,476,553 		JBrowse link
G Vdr vitamin D receptor increases expression ISO Deferoxamine results in increased expression of VDR mRNA CTD PMID:20368581 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
increases secretion
increases expression		 ISO
EXP		 Deferoxamine inhibits the reaction [LCN2 protein results in decreased secretion of VEGFA protein]
Deferoxamine results in increased secretion of VEGFA protein
[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA; Deferoxamine promotes the reaction [[HIF1A protein binds to VEGFA promoter] which results in increased expression of VEGFA mRNA]; Deferoxamine promotes the reaction [Potassium Dichromate results in increased expression of VEGFA protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA]; MIR184 mRNA inhibits the reaction [[Deferoxamine co-treated with tert-Butylhydroperoxide] results in increased expression of VEGFA mRNA]
Deferoxamine results in increased expression of VEGFA mRNA; Deferoxamine results in increased expression of VEGFA protein		 CTD PMID:10613739 PMID:12213806 PMID:15075239 PMID:16227210 PMID:17114340 More... NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Vhl von Hippel-Lindau tumor suppressor multiple interactions ISO VHL protein mutant form affects the reaction [Deferoxamine results in decreased susceptibility to Hydrogen Peroxide] CTD PMID:18515279 NCBI chr 4:146,772,483...146,779,376
Ensembl chr 4:146,772,468...146,779,377 		JBrowse link
G Wt1 WT1 transcription factor multiple interactions ISO [cobaltous chloride co-treated with Deferoxamine] results in increased expression of WT1 mRNA CTD PMID:12738801 NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643 		JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions ISO Deferoxamine promotes the reaction [Palmitic Acid results in increased expression of XBP1 protein] CTD PMID:32283200 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19911
    role 19854
      biological role 19852
        inhibitor 18926
          ferroptosis inhibitor 8097
            desferrioxamine B 273
              desferrioxamine B mesylate 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19911
    subatomic particle 19909
      composite particle 19909
        hadron 19880
          baryon 19880
            nucleon 19909
              atomic nucleus 19880
                atom 19909
                  main group element atom 19849
                    p-block element atom 19849
                      carbon group element atom 19766
                        carbon atom 19785
                          organic molecular entity 19785
                            heteroorganic entity 19541
                              organochalcogen compound 19301
                                organooxygen compound 19193
                                  carbon oxoacid 18681
                                    carboxylic acid 18678
                                      carboacyl group 17728
                                        univalent carboacyl group 17728
                                          carbamoyl group 17548
                                            carboxamide 17580
                                              hydroxamic acid 6337
                                                desferrioxamine 273
                                                  acyclic desferrioxamine 273
                                                    desferrioxamine B 273
                                                      desferrioxamine B mesylate 0
paths to the root